PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs. Intensive Chemo if fit patients with AML.
Daraxonrasib looks like a promising drug for RAS-mutant NSCLC, too.
Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm
Weitere Episoden von „OncoPharm“



Verpasse keine Episode von “OncoPharm” und abonniere ihn in der kostenlosen GetPodcast App.








